the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
The main purpose of this study is to explore the sequential therapeutic effect of
 CD19-targeted and CD20-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of
 Diffuse Large B Cell Lymphoma(DLBCL)
The anti-CD20 antibody has been broadly used in the treatment of B cell malignancies and
 exhibited good clinical outcomes. The CD19-targeted CAR-T has shown excellent therapeutic
 efficiency in B cell malignancies,especially in acute lymphocytic leukemia. However, patients
 treated with CD19-targeted CAR-T may face relapse of CD19 mutation. Therefore we attempt to
 treat Diffuse Large B Cell Lymphoma(DLBCL) patients by sequential therapy of the 2 targets
 and hope to combine their advantages.
Inclusion Criteria:

 1. CD19-expressing and CD20-expressing Diffuse Large B Cell Lymphoma(DLBCL) must be
 assured and must be relapsed or refractory disease after at least one standard
 chemotherapy and one salvage regimen. According to current traditional therapies,
 there must be no available alternative curative therapies and subjects must be either
 ineligible for allogeneic stem cell transplant (SCT), have refused SCT, or have
 disease activity that prohibits SCT at this time.

 2. Patients enrolled must have an evaluated score above 60 with KPS.

 3. Expected survival time of patients enrolled is over 3 months.

 4. Gender is not limited, age from 14 years to 75 years.

 5. Patients must have measurable or evaluable disease at the time of enrollment, which
 may include any evidence of disease including minimal residual disease detected by
 flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.

 6. Patients are expected to survive for more than 3 months by their physicians at the
 time of enrollment.

 7. Adequate absolute CD3 count estimated need to be assured for obtaining target cell
 dose based on dosage cohorts.

 8. Subjects with the following CNS status are eligible only in the absence of neurologic
 symptoms suggestive of CNS leukemia, such as cranial nerve palsy: CNS 1, defined as
 absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless
 of the number of WBCs; CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin
 positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm CNS3
 with marrow disease who has failed salvage systemic and intensive IT chemotherapy (and
 therefore not eligible for radiation)

 9. Patients with isolated CNS relapse will be eligible if they have previously been
 treated with cranial radiation (at least 1800 cGy).

 10. Ability to give informed consent.

 11. Females of child-bearing potential must have a negative pregnancy test because of the
 potentially dangerous effects on the fetus.

 12. Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by
 MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or
 left ventricular ejection fraction greater than or equal to 50% by ECHO.

 13. Renal function: Creatinine level of peripheral blood is required no greater than
 133umol/L.

 14. Patients with history of allogeneic stem cell transplantation are eligible if there is
 no evidence of active GVHD and no longer taking immunosuppressive agents for at least
 30 days prior to enrollment.

 15. Patients volunteer to participate in the research

 Exclusion Criteria:

 Subjects meeting any of the following criteria are not eligible for participation in the
 study:

 1. Patients are evaluated below 50 scores with KPS.

 2. Evident signs suggesting that patients are potentially allergic to cytokines.

 3. Frequent infection history and recent infection is uncontrolled.

 4. Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi
 anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure
 syndrome

 5. Active acute or chronic graft-versus-host disease (GVHD) or requirement of
 immunosuppressant medications for GVHD within 4 weeks of enrollment.

 6. Concurrent use of systemic steroids or chronic use of immunosuppressant medications.
 Recent or current use of inhaled steroids is not exclusionary. For additional details
 regarding use of steroid and immunosuppressant medications.

 7. Pregnancy and nursing females. HIV infection.

 8. Active hepatitis B or active hepatitis C.

 9. Participation in a prior investigational study within 4 weeks prior to enrollment or
 longer if required by local regulation. Participation in non-therapeutic research
 studies is allowed.

 10. Class III/IV cardiovascular disability according to the New York Heart Association
 Classification.

 11. Patients with a known history or prior diagnosis of other serious immunologic,
 malignant or inflammatory disease.

 12. Other situations we think not eligible for participation in the research.